Gynecologic Oncology
Netris Pharma’s clinical research is centered on advanced endometrial carcinoma and cervix carcinoma, with studies focused on patients whose disease has progressed or relapsed after prior systemic chemotherapy.
- Locally advanced disease
- Metastatic disease
- Recurrent endometrial cancer
- Recurrent cervical cancer
The sponsor’s interest in this area reflects a focus on difficult-to-treat gynecologic malignancies requiring new treatment options.
Immuno-Oncology
Its research activity includes combinations involving pembrolizumab, highlighting an interest in immune-based cancer therapy for gynecologic tumors.
- Checkpoint inhibition
- Combination immunotherapy
- Tumor immune response
This area connects the sponsor’s oncology portfolio with treatments designed to enhance anti-tumor immune activity.
Targeted Antibody Therapy
Netris Pharma is evaluating a humanized monoclonal antibody directed against Netrin-1, placing emphasis on antibody-based approaches in solid tumor treatment.
- Monoclonal antibody therapy
- Netrin-1 targeting
- Biological activity in solid tumors
The research interest extends to tumor-directed biologic agents used alongside established anticancer regimens.
Combination Cancer Regimens
The sponsor’s trial portfolio examines carboplatin, paclitaxel, and immunotherapy combinations in advanced gynecologic cancers.
- Platinum-based chemotherapy
- Taxane-based therapy
- Multi-agent treatment strategies
These studies reflect a therapeutic focus on integrating cytotoxic and biologic agents in oncology.
Clinical Activity and Safety Assessment
Research conducted by the sponsor includes evaluation of treatment safety and anti-tumor activity in a multicenter setting across collaborating sites in France.
- Adverse event monitoring
- Objective response assessment
- Multicenter oncology research
The clinical program is concentrated on advanced disease management in European oncology practice.
